Why carry out this study?
|
Surgery is the only option to remove a pterygium, and several surgical techniques have been developed over the years to try and reduce the pterygium recurrence rate. |
Randomized controlled trials and meta-analysis have failed to show a statistical superiority of conjunctival autograft or limbal conjunctival autograft over amniotic membrane graft for primary pterygium surgery. |
The purpose of this review was to compare the “real-life” effectiveness of these three surgical techniques in terms of pterygium recurrence based on the retrospective published data in the literature. |
What was learned from the study?
|
Conjunctival autograft, limbal conjunctival autograft and amniotic membrane graft all seem like reasonable options that could be considered in primary pterygium surgery. |
Amniotic membrane graft can be particularly useful in the case of subsequent glaucoma surgery or in the case of double-headed pterygia; the recurrence rate is lowest when the membrane is glued to the sclera. |
New data suggest that combining amniotic membranes with conjunctival autograft or limbal conjunctival autograft can yield very low recurrence rates, but further studies are needed to confirm these results. |
Introduction
Methods
Surgical Procedures
Conjunctival Autograft
Limbal Conjunctival Autograft
Amniotic Membrane Graft
Search Methods
Statistical Analysis
Outcome of Interest
Results
Conjunctival Autograft
Year | Author (journal) | City/state, country | Duration of follow-up, months (mean ± SD) | Surgical technique | N | Type of fixation used | Adjuvant use of MMC | Postoperative treatment | Recurrence rate | Definition of recurrence |
---|---|---|---|---|---|---|---|---|---|---|
1993 | Riordan Eva et al. (Eye) | London, England | 15 | Conjunctival autograft | 15 | – | – | – | 14.00% | Fibrovascular proliferation outreaching the limbus |
1997 | Prabhasawat et al. (Ophthalmology) | Florida, United States | 24.4 ± 20.9 | Conjunctival autograft | 78 | Vicryl 8–0 or 9–0 sutures | – | CTC + AB, 1 month | 2.60% | Fibrovascular proliferation outreaching the limbus |
2000 | Ma et al. (BJO) | Taoyuan, Taiwan | 22.8 ± 18.2 | Conjunctival autograft | 56 | Vicryl 8–0 sutures | – | CTC + AB 2-4x/d | 5.40% | Fibrovascular proliferation outreaching the limbus |
2003 | Syam et al. (Ophthalmology) | Brighton, England | 27.3 | Conjunctival autograft | 30 | Vicryl 8–0 sutures | – | CTC + AB 4x/d, 4 weeks | 3.30% | Fibrovascular proliferation outreaching the limbus |
2005 | Fernandes et al. (Eye) | Hyderabad, India | 6.4 ± 8.8 | Conjunctival autograft | 345 | Nylon 10–0 + vicryl 8–0 sutures | – | CTC 6 weeks + AB 1 week | 12.20% | Fibrovascular proliferation outreaching the limbus > 1.5 mm |
2005 | Koranyi et al. (Acta Ophthalmol Scand) | Stockholm, Sweden | 23.0 ± 20.0 | Conjunctival autograft | 123 | Sutures | – | CTC 6x/d 6 weeks + AB 2x/d 1 week | 13.8% at 6 months | Fibrovascular proliferation outreaching the limbus |
2005 | Koranyi et al. (Acta Ophthalmol Scand) | Stockholm, Sweden | 23.0 ± 20.0 | Conjunctival autograft | 258 | Biologic glue | – | CTC 6x/d 6 weeks + AB 2x/d 1 week | 5.4% at 6 months | Fibrovascular proliferation outreaching the limbus > 1 mm |
2005 | Mejia et al. (Cornea) | Medellin, Columbia | 9 | Conjunctival autograft | 88 | Nylon 10–0 sutures | – | CTC 3x/d 2 weeks | 1.10% | Fibrovascular proliferation outreaching the limbus > 1 mm |
2008 | Bahar et al. (Curr Eye Res) | Ontario, Canada | 9.0 ± 2.6 | Conjunctival autograft | 70 | Biologic glue | – | CTC + AB 4x/d 4 weeks | 4.30% | Fibrovascular proliferation outreaching the limbus |
2008 | Bahar et al. (Curr Eye Res) | Ontario, Canada | 9.8 ± 4.5 | Conjunctival autograft | 91 | Biologic glue | – | CTC + AB 4x/d 4 weeks | 12.10% | Fibrovascular proliferation outreaching the limbus |
2010 | Sarnicola et al. (Cornea) | Grosseto, Italy | 24 | Conjunctival autograft | 111 | Biologic glue | – | CTC + AB 4x/d 2 weeks | 4.50% | Fibrovascular proliferation outreaching the limbus |
2011 | Nieuwendaal et al. (Cornea) | Amsterdam, Netherlands | Minimum of 12 months | Conjunctival autograft | 28 | Biologic glue | – | CTC tapered over 3 months + AB 2 weeks | 3.57% | Fibrovascular proliferation outreaching the limbus |
2014 | Cagatay et al. (Postgrad Med) | Kars, Turkey | 21.5 ± 5.3 | Conjunctival autograft | 53 | Vicryl 8–0 sutures | – | CTC + AB 4x/d 4 weeks | 7.50% | Fibrovascular proliferation outreaching the limbus > 1 mm |
2014 | Cagatay et al. (Postgrad Med) | Kars, Turkey | 22.1 ± 5.2 | Conjunctival autograft | 53 | Biologic glue | – | CTC + AB 4x/d 4 weeks | 1.90% | Fibrovascular proliferation outreaching the limbus > 1 mm |
2015 | Boucher et al. (Can J Ophthalmol) | Ottawa, Canada | 12 | Conjunctival autograft | 20 | Biologic glue | – | CTC 4x/j 3 months + AB 4x/d 1 week | 5.00% | Fibrovascular proliferation outreaching the limbus > 1 mm |
2018 | Bilge et al. (Saudi J Ophthalmol) | Istanbul, Turkey | 11.7 | Conjunctival autograft | 21 | polypropylene 8–0 sutures | – | CTC + AB 4x/j 4 weeks | 4.8% at 6 months | Fibrovascular proliferation outreaching the limbus |
2018 | Arriola-Villalobos et al. (JFO) | Madrid, Spain | 7.82 ± 8.23 | Conjunctival autograft | 264 | Biologic glue | – | CTC + AB 5x/d tapered over 5 weeks | 6.40% | Fibrovascular proliferation outreaching the limbus > 1 mm |
2018 | Malla et al. (Int J Ophthalmol) | Nanjing, China | Minimum of 12 months | Conjunctival autograft | 37 | Vicryl 8–0 sutures | – | CTC + AB 3x/d tapered over 1 month | 24.30% | Fibrovascular proliferation outreaching the limbus |
2019 | Röck et al. (Med Sci Monit) | Tübingen, Germany | 12 | Conjunctival autograft | 203 | Vicryl 8–0 and 9–0 sutures | – | CTC 4x/d tapered over 3 months + AB 4x/d 2 weeks | 6.4% at 12 months | - |
Limbal Conjunctival Autograft
Year | Author (journal) | City/state, country | Duration of follow-up, months (mean ± SD) | Surgical technique | N | Type of fixation used | Adjuvant use of MMC | Postoperative treatment | Recurrence rate | Definition of recurrence |
---|---|---|---|---|---|---|---|---|---|---|
2005 | Mejia et al. (Cornea) | Medlin, Columbia | 9 | Limbal conjunctival autograft | 24 | Nylon 10–0 sutures | – | CTC 3x/d 2 weeks | 4.20% | - |
2005 | Fernandes et al. (Eye) | Hyderabad, India | 6.4 ± 8.8 | Limbal conjunctival autograft | 52 | Vicryl 8–0 + nylon 10–0 sutures | – | CTC 6 weeks + AB 1 week | 17.30% | Fibrovascular proliferation outreaching the limbus |
2012 | Han et al. (Ophthalmologica) | Seongnam, Korea | 18.9 ± 9.2 | Limbal conjunctival autograft | 82 | Vicryl 8–0 + nylon 10–0 sutures | – | CTC + AB 4x/d 1 month | 2.40% | - |
2015 | Masters et al. (Cornea) | Tennessee, USA | 46.4 ± 49.8 | Limbal conjunctival autograft | 176 | Vicryl 8–0 + nylon 10–0 sutures | – | CTC + AB 4x/d 1 week then 2x/d 2 weeks | 0.60% | Fibrovascular proliferation outreaching the limbus |
2018 | Hwang et al. (BMC Ophthalmology) | Gyeonggi-do, Korea | 19 ± 4.9 | Limbal conjunctival autograft | 78 | Biologic glue | 0.02% 2 min | CTC + AB 4x/d 1 month | 2.60% | Fibrovascular proliferation outreaching the limbus |
2020 | Yang et al. (Graefes Arch Clin Exp Ophthalmol) | Kangwon, Korea | 12 | Limbal conjunctival autograft | 48 | Vicryl 8–0 + nylon 10–0 sutures | – | CTC + AB 4x/d 1 month | 8.30% | Fibrovascular proliferation outreaching the limbus |
2020 | Yang et al. (Graefes Arch Clin Exp Ophthalmol) | Kangwon, Korea | 12 | Limbal conjunctival autograft | 49 | Vicryl 8–0 sutures | – | CTC + AB 4x/d 1 month | 18.40% | Fibrovascular proliferation outreaching the limbus |
Amniotic Membrane Graft
Year | Author (journal) | City/state, country | Duration of follow-up, months (mean ± SD) | Surgical technique | N | Type of fixation used | Adjuvant use of MMC | Postoperative treatment | Recurrence rate | Definition of recurrence |
---|---|---|---|---|---|---|---|---|---|---|
2005 | Fernandes et al. (Eye) | Hyderabad, India | 6.4 ± 8.8 | AMG inlay | 105 | Vicryl 8–0 + nylon 10–0 sutures | – | CTC 6 weeks + AB 1 week | 26.70% | Fibrovascular proliferation outreaching the limbus |
2013 | Okoye et al. (Niger J Clin Pract) | Andra Prand., India | 3 | AMG inlay | 26 | Vicryl 8–0 sutures | – | 3.85% | Fibrovascular proliferation outreaching the limbus | |
2013 | Kurna et al. (Eur J Ophthalmol) | Istanbul, Turkey | AMG | 22 | Vicryl 8–0 + nylon 10–0 sutures | – | – | 27.30% | Fibrovascular proliferation outreaching the limbus | |
2018 | Rosen et al. (Cornea) | California, USA | 17.3 ± 0.8 | AMG inlay | 527 | Biologic glue | 0.02% 30 s | CTC 6x/d tapered over 2 months + AB 4x/d 1 week | 3.60% | Fibrovascular proliferation outreaching the limbus |
2018 | Malla et al. (Int J Ophthalmol) | Nanjing, China | Minimum of 12 months | AMG-L inlay | 34 | Vicryl 8–0 sutures | – | CTC + AB 3x/d tapered over 1 month | 29.40% | Fibrovascular proliferation outreaching the limbus |
2019 | Röck et al. (Med Sci Monit) | Tübingen, Germany | 12 | AMG inlay | 34 | Vicryl 8–0 + 9–0 sutures | – | CTC 4x/d tapered over 3 months + AB 4x/d 2 weeks | 14.7% at 12 months | - |
Combined Techniques
Year | Author (journal) | City/state, country | Duration of follow-up, months (mean ± SD) | Surgical technique | N | Type of fixation used | Adjuvant use of MMC | Postoperative treatment | Recurrence rate | Definition of recurrence |
---|---|---|---|---|---|---|---|---|---|---|
2005 | Fernandes et al. (Eye) | Hyderabad, India | 6.4 ± 8.8 | Conjunctival autograft + AMG inlay under the conjunctiva | 20 | Vicryl 8–0 + nylon 10–0 sutures | – | CTC 6 weeks + AB 1 week | 15.00% | Fibrovascular proliferation outreaching the limbus |
2018 | Malla et al. (Int J Ophthalmol) | Nanjing, China | Minimum of 12 months | Conjunctival autograft + AMG-L overlay | 33 | Vicryl 8–0 sutures | – | CTC + AB 3x/d tapered over 1 month | 3.00% | Fibrovascular proliferation outreaching the limbus |
2020 | Shusko et al. (Clin Ophthalmol) | Florida, USA | 28 | Conjunctival-limbal autograft + AMG-L under the conjunctiva | 493 | Biologic glue | – | CTC 4x/d 2 weeks then tapered + AB 1 week | 1.20% | Fibrovascular proliferation outreaching the limbus > 1 mm |